In this model, mAKT and mAKT/NRAS are specifically and stably expressed in hepatocytes, activating mTORC1 and driving HCC development, as indicated by elevated p-S6 and HCC marker arginase and cholangiocarcinoma marker CK19, respectively (Figure 2C) 11. This evidence concerns the gene KRT19 and cholangiocarcinoma.